Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation [PDF]
JAK2V617F mutation is found in about 60% of cases of essential thrombocytemia (ET) and represents a driving mutation. Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet (PLT) count.
Giovanni Caocci +3 more
doaj +8 more sources
The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms. [PDF]
Background/aim JAK2V617F mutation is expressed in almost all polycthemia vera (PV), 55% of essential thrombocythemia (ET), and 65% of primary myelofibrosis (PMF) patients.
Şahin E +4 more
europepmc +7 more sources
JAK2V617F mutation drives vascular resident macrophages toward a pathogenic phenotype and promotes dissecting aortic aneurysm [PDF]
JAK2V617F mutation is associated with an increased risk for athero-thrombotic cardiovascular disease, but its role in aortic disease development remains unknown. Here, the authors show that JAK2V617F mutation drives vascular resident macrophages toward a
Rida Al-Rifai +26 more
doaj +3 more sources
A substitution mutation of valine to phenylalanine at codon encoding position 617 of the Janus kinase 2 (JAK2) gene (JAK2V617F) has been detected in myeloid cells of some individuals with higher levels of proinflammatory cytokine production such as ...
Rongqing Li +27 more
doaj +4 more sources
JAK2V617F Mutation in Endothelial Cells of Patients with Atherosclerotic Carotid Disease [PDF]
Objective: It has been shown that clonal mutations occur in hematopoietic stem cells with advancing age and increase the risk of death due to atherosclerotic vascular diseases, similarly to myeloproliferative neoplasms.
Reyhan Diz Küçükkaya +4 more
doaj +3 more sources
JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study. [PDF]
Key Points • The JAK2V617F mutation prevalence in patients with ischemic stroke is 11.3%.• Patients with ischemic stroke are 2.4 times more likely to have the JAK2V617F mutation than matched controls.
Kristiansen MH +6 more
europepmc +2 more sources
Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2V617F mutation. [PDF]
The classic BCR-ABL1-negative myeloproliferative neoplasm (MPN) is a highly heterogeneous hematologic tumor that includes three subtypes, namely polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (PMF).
Fan W +12 more
europepmc +2 more sources
Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2 V617F mutation. [PDF]
Background JAK2V617F and Calreticulin (CALR) mutations are the most frequent molecular causes of Phi-negative myeloproliferative neoplasms (MPN). Patients with CALR mutations are at lower risk of thrombosis than patients with JAK2V617F.
Guy A +6 more
europepmc +2 more sources
Frequency of JAK2V617F Mutation Zygosity and Impact on Disease Outcome in MPN Patients. [PDF]
Background: Myeloproliferative Neoplasm (MPN) is a clonal disorder of blood progenitor cells during haematopoiesis. JAK2V617F mutation represents one of the major identified genetic reasons of MPN disorder.
Khazeem MM.
europepmc +2 more sources
Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study. [PDF]
It is unknown if the somatic mutations in chronic myeloproliferative neoplasms (MPNs), JAK2V617F and Calreticulin, are associated with oxidative stress, or impaired mitochondrial defense against reactive oxygen species.
Sørensen AL +8 more
europepmc +2 more sources

